Eur Rev Med Pharmacol Sci 2021; 25 (11): 3933-3933
DOI: 10.26355/eurrev_202106_26026

Blocking VRK2 suppresses pulmonary adenocarcinoma progression via ERK1/2/AKT signal pathway by targeting miR-145-5p

Y. Mu, W.-J. Liu, L.-Y. Bie, X.-Q. Mu, Y.-Q. Zhao

Department of Oncology, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan Province, China.


The article “Blocking VRK2 suppresses pulmonary adenocarcinoma progression via ERK1/2/AKT signal pathway by targeting miR-145-5p, by Y. Mu, W.-J. Liu, L.-Y. Bie, X.-Q. Mu, Y.-Q. Zhao, published in Eur Rev Med Pharmacol Sci 2021; 25 (1): 145-153–DOI: 10.26355/eurrev_202101_24378–PMID: 33506902” has been withdrawn from the authors since the design of the manuscript was not rigorous enough (there were some flaws in some experiments).

The authors explain that they will perform further experiments.

The Publisher apologizes for any inconvenience this may cause.

https://www.staging.europeanreview.org/article/24378

Free PDF Download

To cite this article

Y. Mu, W.-J. Liu, L.-Y. Bie, X.-Q. Mu, Y.-Q. Zhao
Blocking VRK2 suppresses pulmonary adenocarcinoma progression via ERK1/2/AKT signal pathway by targeting miR-145-5p

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 11
Pages: 3933-3933
DOI: 10.26355/eurrev_202106_26026